Guillain-Barré syndrome

Area of Science:

• Neuroscience
• Immunology
• Infectious Diseases

Background:

• Guillain-Barré syndrome (GBS) is a group of acute peripheral neuropathies with diverse mechanisms.
• The acute inflammatory demyelinating polyradiculoneuropathy (AIDP) subtype involves T-cells and myelin proteins, but antibody and complement roles are also suggested.
• Axonal subtypes, acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN), are increasingly understood.

Purpose of the Study:

• To elucidate the immunological mechanisms underlying Guillain-Barré syndrome subtypes.
• To investigate the role of Campylobacter jejuni infections and ganglioside antibodies in axonal GBS.
• To review current treatment efficacies for Guillain-Barré syndrome.

Main Methods:

• Review of existing literature on GBS pathogenesis and clinical studies.
• Analysis of antibody targets (gangliosides) in relation to specific GBS subtypes.
• Examination of findings from international randomized trials on GBS treatments.

Main Results:

• Axonal GBS (AMAN, AMSAN) is strongly associated with antibodies to axolemmal gangliosides, often following Campylobacter jejuni infection.
• Campylobacter jejuni lipo-oligosaccharides mimic gangliosides, triggering cross-reactive antibodies (e.g., anti-GM1, anti-GQ1b).
• Plasma exchange and intravenous immunoglobulin show equivalent efficacy in hastening GBS recovery, while corticosteroids are less effective.

Conclusions:

• Antibody-mediated attack on gangliosides at the nodes of Ranvier is a key mechanism in axonal GBS.
• Campylobacter jejuni is a significant trigger for axonal GBS through molecular mimicry.
• Effective treatments for GBS include plasma exchange and IVIg, but further research is needed to address persistent disability.